dc.contributor.authorEfraim, Yael
dc.contributor.authorSarig, Hadar
dc.contributor.authorCohen Anavy, Noa
dc.contributor.authorSarig, Udi
dc.contributor.authorde Berardinis, Elio
dc.contributor.authorChaw, Su-Yin
dc.contributor.authorKrishnamoorthi, Muthukumar
dc.contributor.authorKalifa, Jérôme
dc.contributor.authorBogireddi, Hanumakumar
dc.contributor.authorDuc, Thang Vu
dc.contributor.authorKofidis, Theodoros
dc.contributor.authorBaruch, Limor
dc.contributor.authorBoey, Freddy Yin Chiang
dc.contributor.authorVenkatraman, Subbu Subramanian
dc.contributor.authorMachluf, Marcelle
dc.identifier.citationEfraim, Y., Sarig, H., Cohen Anavy, N., Sarig, U., de Berardinis, E., Chaw, S.-Y., et al. (2017). Biohybrid cardiac ECM-based hydrogels improve long term cardiac function post myocardial infarction. Acta Biomaterialia, 50, 220-233.en_US
dc.description.abstractInjectable scaffolds for cardiac tissue regeneration are a promising therapeutic approach for progressive heart failure following myocardial infarction (MI). Their major advantage lies in their delivery modality that is considered minimally invasive due to their direct injection into the myocardium. Biomaterials comprising such scaffolds should mimic the cardiac tissue in terms of composition, structure, mechanical support, and most importantly, bioactivity. Nonetheless, natural biomaterial-based gels may suffer from limited mechanical strength, which often fail to provide the long-term support required by the heart for contraction and relaxation. Here we present newly-developed injectable scaffolds, which are based on solubilized decellularized porcine cardiac extracellular matrix (pcECM) cross-linked with genipin alone or engineered with different amounts of chitosan to better control the gel’s mechanical properties while still leveraging the ECM biological activity. We demonstrate that these new biohybrid materials are naturally remodeled by mesenchymal stem cells, while supporting high viabilities and affecting cell morphology and organization. They exhibit neither in vitro nor in vivo immunogenicity. Most importantly, their application in treating acute and long term chronic MI in rat models clearly demonstrates the significant therapeutic potential of these gels in the long-term (12 weeks post MI). The pcECM-based gels enable not only preservation, but also improvement in cardiac function eight weeks post treatment, as measured using echocardiography as well as hemodynamics. Infiltration of progenitor cells into the gels highlights the possible biological remodeling properties of the ECM-based platform.en_US
dc.description.sponsorshipNRF (Natl Research Foundation, S’pore)en_US
dc.format.extent39 p.en_US
dc.relation.ispartofseriesActa Biomaterialiaen_US
dc.rights© 2016 Acta Materialia Inc. (published by Elsevier Ltd). This is the author created version of a work that has been peer reviewed and accepted for publication in Acta Biomaterialia, published by Elsevier Ltd on behalf of Acta Materialia Inc. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document.  The published version is available at: [http://dx.doi.org/10.1016/j.actbio.2016.12.015].en_US
dc.subjectCardiac tissue engineeringen_US
dc.subjectInjectable scaffolden_US
dc.titleBiohybrid cardiac ECM-based hydrogels improve long term cardiac function post myocardial infarctionen_US
dc.typeJournal Article
dc.contributor.schoolSchool of Materials Science and Engineeringen_US
dc.description.versionAccepted versionen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record